TABLE 16 Protective Efficacy (PE) and Reported 95% Confidence Intervals (CI) for Outcomes During the 11 Months After Last Dose of SP or Placebo

Location, Country

Ifakara, Tanzania

Navrongo, Ghana

Manhiça, Mozambique

Number of Subjects

Placebo

344

1216

755

IPTi-SP

344

1197

748

Episodes of Clinical Malaria

Placebo

166

826

336

IPTi-SP

146

854

344

% PE

14

−5

−16

95 CI (%)

(−11,33)

(−22, 9)

(−51, 11)

p-value

0.25

0.49

0.29

Episodes of Hospitalization with Malaria Parasites

Placebo

34

54

58

IPTi-SP

30

52

74

% PE

12

2

−39

95 CI (%)

(−45, 47)

(−57, 39)

(−130, 15)

p-value

0.61

0.94

0.19

Episodes of All-Cause Hospital Admissions

Placebo

108

203

205

IPTi-SP

111

224

202

% PE

−1

−12

4

95 CI (%)

(−38, 25)

(−43, 11)

(−34, 32)

p-value

0.94

0.34

0.79

Subjects with Anemia

Placebo

40

102

64

IPTi-SP

35

117

61

% PE

12

−17

4

95 CI (%)

(−34, 43)

(−59, 15)

(−35, 31)

p-value

0.54

0.34

0.82

SOURCE: Compiled from data in the report of the Consortium’s Statistical Working Group (IPTi Consortium, 2007b).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement